Triflusal vs. aspirin
This article was originally published in The Tan Sheet
Aspirin and anti-clotting drug triflusal are similarly effective in secondary stroke prevention but triflusal poses less hemorrhage risk, according to two studies presented. Triflusal, an antiplatelet agent structurally related to aspirin, was developed in Spain about 20 years ago and is licensed for use in parts of Europe, Asia and Latin America; approval never has been sought in the U.S., according to the American Stroke Association. One study of 429 patients was conducted in Buenos Aires, Argentina; another trial looked at 2,108 patients in Spain and Portugal. Both compared the efficacy of triflusal 600 mg to aspirin 325 mg among subjects who had suffered a recent TIA or stroke
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC